Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III Sells 2,326 Shares

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 2,326 shares of Pulmonx stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $6.53, for a total value of $15,188.78. Following the completion of the transaction, the director now owns 1,069,648 shares in the company, valued at $6,984,801.44. The trade was a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Pulmonx Price Performance

Shares of LUNG opened at $6.10 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The company has a market capitalization of $240.89 million, a price-to-earnings ratio of -4.15 and a beta of 0.66. The business’s 50-day moving average is $6.42 and its 200-day moving average is $6.88. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $14.84.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The company had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. During the same quarter last year, the business posted ($0.39) EPS. Equities research analysts expect that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LUNG shares. Stifel Nicolaus dropped their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Citigroup reiterated a “neutral” rating and issued a $7.50 target price (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Finally, Wells Fargo & Company reduced their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. 272 Capital LP purchased a new stake in shares of Pulmonx during the 3rd quarter worth about $25,000. nVerses Capital LLC acquired a new position in Pulmonx in the third quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Pulmonx during the second quarter valued at approximately $37,000. R Squared Ltd acquired a new stake in Pulmonx in the fourth quarter valued at approximately $46,000. Finally, Hsbc Holdings PLC acquired a new stake in Pulmonx in the second quarter valued at approximately $93,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.